Prosensa Holding NV
(NASDAQ : RNA)

( )
RNA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.79%79.141.2%$541.48m
AMGNAmgen Inc.
-0.28%185.991.2%$522.30m
GILDGilead Sciences, Inc.
0.08%71.520.9%$518.25m
BIIBBiogen Inc.
0.16%297.341.2%$439.96m
NKTRNektar Therapeutics
-3.97%55.865.6%$383.38m
SRPTSarepta Therapeutics, Inc.
-2.63%149.6516.6%$325.83m
VRTXVertex Pharmaceuticals Incorporated
-0.67%156.571.9%$253.87m
REGNRegeneron Pharmaceuticals, Inc.
-2.34%329.042.6%$243.76m
ILMNIllumina, Inc.
-0.56%286.053.5%$191.71m
AAgilent Technologies, Inc.
0.40%63.041.5%$180.09m
BLUEBluebird Bio, Inc.
2.32%187.3515.7%$156.91m
ALXNAlexion Pharmaceuticals, Inc.
1.04%125.812.0%$149.34m
EXASExact Sciences Corporation
-0.74%68.8225.5%$144.87m
BMRNBioMarin Pharmaceutical Inc.
0.09%98.434.4%$139.42m
INCYIncyte Corporation
-1.28%72.492.5%$126.38m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.